Literature DB >> 28433721

Optimizing the restored chemotactic behavior of anticancer agent Salmonella enterica serovar Typhimurium VNP20009.

Katherine M Broadway1, Seungbeum Suh2, Bahareh Behkam3, Birgit E Scharf4.   

Abstract

Bacteria, including strains of Salmonella, have been researched and applied as therapeutic cancer agents for centuries. Salmonella are particularly of interest due to their facultative anaerobic nature, facilitating colonization of differentially oxygenated tumor regions. Additionally, Salmonella can be manipulated with relative ease, resulting in the ability to attenuate the pathogen or engineer vectors for drug delivery. It was recently discovered that the anti-cancer Salmonella enterica serovar Typhimurium strain VNP20009 is lacking in chemotactic ability, due to a non-synonymous single nucleotide polymorphism in cheY. Replacing the mutated copy of cheY with the wild-type sequence restored chemotaxis to 70% of the parental strain. We aimed to investigate further if chemotaxis of VNP20009 can be optimized. By restoring the gene msbB in VNP20009 cheY+, which confers attenuation by lipid A modification, we observed a 9% increase in swimming speed, 13% increase in swim plate performance, 19% increase in microfluidic device partitioning towards the attractant at the optimum concentration gradient, and mitigation of a non-motile cell subpopulation. We conclude that chemotaxis can be enhanced further but at the cost of changing one defining characteristic of VNP20009. A less compromised strain might be needed to employ for investigating bacterial chemotaxis in tumor interactions.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bacterial anti-tumor therapy; Chemotaxis; Microfluidic chemotaxis assay; Tumor-colonizing bacteria

Mesh:

Substances:

Year:  2017        PMID: 28433721     DOI: 10.1016/j.jbiotec.2017.04.006

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  6 in total

Review 1.  Engineering the gut microbiota to treat chronic diseases.

Authors:  Noura S Dosoky; Linda S May-Zhang; Sean S Davies
Journal:  Appl Microbiol Biotechnol       Date:  2020-07-21       Impact factor: 4.813

2.  Bacteria-driven hypoxia targeting delivery of chemotherapeutic drug proving outcome of breast cancer.

Authors:  Susu Xiao; Huan Shi; Yan Zhang; Yu Fan; Li Wang; Li Xiang; Yanlin Liu; Ling Zhao; Shaozhi Fu
Journal:  J Nanobiotechnology       Date:  2022-04-02       Impact factor: 10.435

Review 3.  Recombinant Attenuated Salmonella enterica as a Delivery System of Heterologous Molecules in Cancer Therapy.

Authors:  Elayne Irene Becerra-Báez; Sergio Enrique Meza-Toledo; Paola Muñoz-López; Luis Fernando Flores-Martínez; Karla Fraga-Pérez; Kevin Jorge Magaño-Bocanegra; Uriel Juárez-Hernández; Armando Alfredo Mateos-Chávez; Rosendo Luria-Pérez
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

Review 4.  Cancer Immunotherapy: Priming the Host Immune Response with Live Attenuated Salmonella enterica.

Authors:  Marco Antonio Hernández-Luna; Rosendo Luria-Pérez
Journal:  J Immunol Res       Date:  2018-09-13       Impact factor: 4.818

Review 5.  Salmonella-Based Targeted Cancer Therapy: Updates on A Promising and Innovative Tumor Immunotherapeutic Strategy.

Authors:  Christian Ronquillo Pangilinan; Che-Hsin Lee
Journal:  Biomedicines       Date:  2019-05-02

6.  Draft genome sequences of Salmonella Oslo isolated from seafood and its laboratory generated auxotrophic mutant.

Authors:  Kadeeja Jazeela; Anirban Chakraborty; Praveen Rai; Ballamoole Krishna Kumar; Shabarinath Srikumar; Scot van Nguyen; Daniel Hurley; Seamus Fanning; Indrani Karunasagar; Vijaya Kumar Deekshit
Journal:  J Genomics       Date:  2020-01-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.